Epidemiology of severe drug hypersensitivity

Seminars in Cutaneous Medicine and Surgery

Volumn 33, Issue 1, 2014, Pages 2-9

  Dodiuk Gad, Roni P ^a,b   Laws, Philip M ^a   Shear, Neil H ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b HAEMEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGINA PECTORIS AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; HLA ANTIGEN;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ARTICLE; DRESS SYNDROME; DRUG ERUPTION; DRUG HYPERSENSITIVITY; ENZYME POLYMORPHISM; EOSINOPHILIA; GENOTYPE; HUMAN; INCIDENCE; MORBIDITY; MORTALITY; POLYPHARMACY; PREVALENCE; RISK FACTOR; SERUM SICKNESS; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; CHEMICALLY INDUCED DISORDER; FEVER; GENETIC POLYMORPHISM; GENETICS; RASH; REVIEW;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; DRUG HYPERSENSITIVITY; DRUG HYPERSENSITIVITY SYNDROME; EOSINOPHILIA; EXANTHEMA; FEVER; GENOTYPE; HLA ANTIGENS; HUMANS; POLYMORPHISM, GENETIC; POLYPHARMACY; RISK FACTORS; STEVENS-JOHNSON SYNDROME;

EID: 84906537377     PISSN: 10855629     EISSN: 15580768     Source Type: Journal    
DOI: 10.12788/j.sder.0057     Document Type: Article

References (111)

1. World Health Organization. The Importance of Pharmacovigilance - Safety Monitoring of Medicinal Products. http://apps.who.int/medicinedocs/en/d/Js4893e/9. html. Accessed January 22, 2014.
2. Pirmohamed M, Friedmann PS, Molokhia M, et al. Phenotype standardization for immune-mediated drug-induced skin injury. Clin Pharmacol Ther. 2011;89(6):896-901.
3. Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol. 2011;71(5):684-700.
4. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995;274(1):29-34.
5. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997;277(4):307-311.
6. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200-1205.
7. Fattinger K, Roos M, Vergeres P, et al. Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine. Br J Clin Pharmacol. 2000;49(2):158-167.
8. Dormann H, Muth-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting. Drug Safety. 2000;22(2):161-168.
9. Runciman WB, Roughead EE, Semple SJ, Adams RJ. Adverse drug events and medication errors in Australia. Int J Qual Health Care. 2003;15 Suppl 1:i49-59.
10. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15-19.
11. Thong BY, Leong KP, Tang CY, Chng HH. Drug allergy in a general hospital: Results of a novel prospective inpatient reporting system. Ann Allerg Asthma Immunol. 2003;90(3):342-347.
12. Park CS, Kim TB, Kim SL, et al. The use of an electronic medical record system for mandatory reporting of drug hypersensitivity reactions has been shown to improve the management of patients in the university hospital in Korea. Pharmacoepidemiol Drug Safety. 2008;17(9):919-925.
13. Fiszenson-Albala F, Auzerie V, Mahe E, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol. 2003;149(5):1018-1022.
14. Hernandez-Salazar A, Rosales SP, Rangel-Frausto S, Criollo E, Archer-Dubon C, Orozco-Topete R. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res. 2006;37(7):899-902.
15. Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol. 1968;80(12):771-793.
16. Beylot C, Bioulac P, Doutre MS. [Acute generalized exanthematic pustuloses (four cases) (author's transl)]. Ann Dermatol Venereol. 1980;107(1-2):37-48.
17. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. J Cut Path. 2001;28(3):113-119.
18. Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157(5):989-996.
19. Roujeau JC, Bioulac-Sage P, Bourseau C, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol. 1991;127(9):1333-1338.
20. Rouchouse B, Bonnefoy M, Pallot B, Jacquelin L, Dimoux-Dime G, Claudy AL. Acute generalized exanthematous pustular dermatitis and viral infection. Dermatologica. 1986;173(4):180-184.
21. Feio AB, Apetato M, Costa MM, Sa J, Alcantara J. [Acute generalized exanthematous pustulosis due to Coxsackie B4 virus]. Acta Med Port. 1997;10(6-7):487-491.
22. Naides SJ, Piette W, Veach LA, Argenyi Z. Human parvovirus B19-induced vesiculopustular skin eruption. Am J Med. 1988;84(5):968-972.
23. Davidovici BB, Pavel D, Cagnano E, Rozenman D, Halevy S. Acute generalized exanthematous pustulosis following a spider bite: report of 3 cases. J Am Acad Dermatol. 2006;55(3):525-529.
24. Davidovici B, Dodiuk-Gad R, Rozenman D, Halevy S. Profile of acute generalized exanthematous pustulosis in Israel during 2002-2005: results of the RegiSCAR Study. IMAJ. 2008;10(6):410-412.
25. Bernard P, Lizeaux-Parneix V, Miossec V, Bonnetblanc JM, Drouet M. HLA et prédisposition génétique dans les pustuloses exanthématiques (PEAG) et les exanthémes maculapapuleux (EMP). Ann Dermatol Venereol. 1995;122:S38-S39.
26. Hotz C, Valeyrie-Allanore L, Haddad C, et al. Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients. Br J Dermatol. 2013.
27. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;209(2):123-129.
28. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in Metabolism of Sulfonamides Predisposing to Idiosyncratic Toxicity. Ann Intern Med. 1986;105(2):179-184.
29. Chaiken BH, Goldberg BI, Segal JP. Dilantin sensitivity; report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. N Engl J Med. 1950;242(23):897-898.
30. Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med. 2011;124(7):588-597.
31. Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013.
32. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Safety. 1999;21(6):489-501.
33. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest. 1988;82(6):1826-1832.
34. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology. 1997;49(2):542-546.
35. Knowles SR, Dewhurst N, Shear NH. Anticonvulsant hypersensitivity syndrome: an update. Expert Opin Drug Safety. 2012;11(5):767-778.
36. Holtzman DM, Kaku DA, So YT. New-onset seizures associated with human immunodeficiency virus infection: causation and clinical features in 100 cases. Am J Med. 1989;87(2):173-177.
37. Oskay T, Karademir A, Erturk OI. Association of anticonvulsant hypersensitivity syndrome with Herpesvirus 6, 7. Epilepsy Res. 2006;70(1):27-40.
38. Scagni P, Morello M, Ramus MV, Agostini M, Pagliero R. Drug-induced hypersensivity syndrome associated with Epstein-Barr virus infection: a pediatric case report. Ped Dermatol. 2009;26(2):229-231.
39. Aihara M, Sugita Y, Takahashi S, et al. Anticonvulsant hypersensitivity syndrome associated with reactivation of cytomegalovirus. Br J Dermatol. 2001;144(6):1231-1234.
40. Hung SI, Chung WH, Liou LB, et al. HLA-B* 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. PNAS. 2005;102(11):4134-4139.
41. Chiu ML, Hu M, Ng MH, et al. Association between HLA-B *58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. Br J Dermatol. 2012;167(1):44-49.
42. Goncalo M, Coutinho I, Teixeira V, et al. HLA-B* 58:01 is a risk factor for allopurinol induced DRESS and SJS/TEN in a Portuguese population. Br J Dermatol. 2013;169(3):660-665.
43. Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013;93(2):153-158.
44. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64(10):1447-1461.
45. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B* region and hypersensitivity reactions to abacavir. Lancet. 2002;359(9312):1121-1122.
46. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics. 2004;14(6):335-342.
47. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568-579.
48. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. Aids. 2005;19(1):97-99.
49. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134-1143.
50. Dreesman A, Hoorens A, Hachimi-Idrissi S. Multiple organ dysfunction syndrome: infection or hypersensitivity reaction? Eur J Emerg Med. 2010;17(4):228-229.
51. Lalic M, Cvejic J, Popovic J, et al. Lamotrigine and valproate pharmacokinetics interactions in epileptic patients. Eur J Drug Metab Pharmacokinet. 2009;34(2):93-99.
52. Chen YC, Chang CY, Cho YT, Chiu HC, Chu CY. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol. 2013;68(3):459-465.
53. Chiou CC, Chung WH, Hung SI, Yang LC, Hong HS. Fulminant type 1 diabetes mellitus caused by drug hypersensitivity syndrome with human herpesvirus 6 infection. J Am Acad Dermatol. 2006;54(2 Suppl):S14-17.
54. Callot V, Roujeau JC, Bagot M, et al. Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Arch Dermatol. 1996;132(11):1315-1321.
55. Chiou CC, Yang LC, Hung SI, et al. Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan. J Eur Acad Dermatol Venereol. 2008;22(9):1044-1049.
56. Yang CY, Dao RL, Lee TJ, et al. Severe cutaneous adverse reactions to antiepileptic drugs in Asians. Neurology. 2011;77(23):2025-2033.
57. Murray DL, Singer DA, Singer AB, Veldman JP. Cefaclor--a cluster of adverse reactions. N Engl J Med. 1980;303(17):1003.
58. Hebert AA, Sigman ES, Levy ML. Serum sickness-like reactions from cefaclor in children. J Am Acad Dermatol. 1991;25(5 Pt 1):805-808.
59. Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol. 2003;2(3):278-299.
60. Misirlioglu ED, Duman H, Ozmen S, Bostanci I. Serum sickness-like reaction in children due to cefditoren. Pediatr Dermatol. 2012;29(3):327-328.
61. Tatum AJ, Ditto AM, Patterson R. Severe serum sickness-like reaction to oral penicillin drugs: three case reports. Ann Allergy Asthma Immunol. 2001;86(3):330-334.
62. Landau M, Shachar E, Brenner S. Minocycline-induced serum sickness-like reaction. J Eur Acad Dermatol Venereol. 2000;14(1):67-68.
63. Aujero MP, Brooks S, Li N, Venna S. Severe serum sickness-like type III reaction to insulin detemir. J Am Acad Dermatol. 2011;64(6):e127-128.
64. Gamarra RM, McGraw SD, Drelichman VS, Maas LC. Serum sickness-like reactions in patients receiving intravenous infliximab. J Emerg Med. 2006;30(1):41-44.
65. Silverstein AM. Clemens Freiherr von Pirquet: explaining immune complex disease in 1906. Nat Immunol. 2000;1(6):453-455.
66. Wolf R, Orion E, Marcos B, Matz H. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol. 2005;23(2):171-181.
67. Zhang Z, Xiang Y, Wang B, et al. Intestinal mucosal permeability of children with cefaclor-associated serum sickness-like reactions. Eur J Pediatr. 2013;172(4):537-543.
68. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet. 2000;356(9241):1587-1591.
69. Knowles S, Shapiro L, Shear NH. Serious dermatologic reactions in children. Curr Opin Pediatr. 1997;9(4):388-395.
70. Kearns GL, Wheeler JG, Childress SH, Letzig LG. Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility. J Pediatr. 1994;125(5 Pt 1):805-811.
71. Katta R, Anusuri V. Serum sickness-like reaction to cefuroxime: a case report and review of the literature. J Drugs Dermatol. 2007;6(7):747-748.
72. Yerushalmi J, Zvulunov A, Halevy S. Serum sickness-like reactions. Cutis. 2002;69(5):395-397.
73. Tolpinrud WL, Bunick CG, King BA. Serum sickness-like reaction: histopathology and case report. J Am Acad Dermatol. 2011;65(3):e83-85.
74. Shah KN, Honig PJ, Yan AC. "Urticaria multiforme": a case series and review of acute annular urticarial hypersensitivity syndromes in children. Pediatrics. 2007;119(5):e1177-1183.
75. Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia: Report of two cases in children. Am J Dis Child. 1922;24(6):526-533.
76. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol. 1956;68(11):355-361.
77. Paquet P, Pierard GE. New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited. Drug Safety. 2010;33(3):189-212.
78. Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Safety. 2002;25(13):965-972.
79. Mittmann N, Knowles SR, Koo M, Shear NH, Rachlis A, Rourke SB. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012;13(1):49-54.
80. Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123(2):e297-304.
81. Struck MF, Illert T, Liss Y, Bosbach ID, Reichelt B, Steen M. Toxic epidermal necrolysis in pregnancy: case report and review of the literature. J Burn Care Res. 2010;31(5):816-821.
82. Harr T, French LE. Stevens-Johnson syndrome and toxic epidermal necrolysis. Chem Immunol Allergy. 2012;97:149-166.
83. Knowles S, Shear NH. Clinical risk management of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Dermatol Ther. 2009;22(5):441-451.
84. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128(1):35-44.
85. Saka B, Barro-Traore F, Atadokpede FA, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries. Int J Dermatol. 2013;52(5):575-579.
86. Fournier S, Bastuji-Garin S, Mentec H, Revuz J, Roujeau JC. Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection. Eur J Clin Microbiol Infect Dis. 1995;14(6):558-559.
87. Grieb G, Alazemi M, Das R, Dunda SE, Fuchs PC, Pallua N. A rare case of toxic epidermal necrolysis with unexpected Fever resulting from dengue virus. Case Rep Dermatol. 2010;2(3):189-194.
88. Khalaf D, Toema B, Dabbour N, Jehani F. Toxic epidermal necrolysis associated with severe cytomegalovirus infection in a patient on regular hemodialysis. Mediterr J Hematol Infect Dis. 2011;3(1):e2011004.
89. Pedrazzoli P, Rosti V, Rossi R, Cazzola M. Toxic epidermal necrolysis following Yersinia enterocolitica infection. Int J Dermatol. 1993;32(1):75.
90. Baldwin BT, Lien MH, Khan H, Siddique M. Case of fatal toxic epidermal necrolysis due to cardiac catheterization dye. J Drugs Dermatol. 2010;9(7):837-840.
91. Ball R, Ball LK, Wise RP, Braun MM, Beeler JA, Salive ME. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system. Pediatric Infect Dis J. 2001;20(2):219-223.
92. Li K, Haber RM. Stevens-Johnson syndrome without skin lesions (Fuchs syndrome): a literature review of adult cases with Mycoplasma cause. Arch Dermatol. 2012;148(8):963-964.
93. Ravin KA, Rappaport LD, Zuckerbraun NS, Wadowsky RM, Wald ER, Michaels MM. Mycoplasma pneumoniae and atypical Stevens-Johnson syndrome: a case series. Pediatrics. 2007;119(4):e1002-1005.
94. Zineh I, Mummaneni P, Lyndly J, et al. Allopurinol pharmacogenetics: assessment of potential clinical usefulness. Pharmacogenomics. 2011;12(12):1741-1749.
95. Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364(12):1126-1133.
96. Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Immunol. 2007;7(4):317-323.
97. Profaizer T, Eckels D. HLA alleles and drug hypersensitivity reactions. Int J Immunogenet. 2012;39(2):99-105.
98. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88(1):60-68.
99. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69(2):187 e181-187 e116.
100. Lopez-Garcia JS, Rivas Jara L, Garcia-Lozano CI, Conesa E, de Juan IE, Murube del Castillo J. Ocular features and histopathologic changes during follow-up of toxic epidermal necrolysis. Ophthalmology. 2011;118(2):265-271.
101. Niemeijer IC, van Praag MC, van Gemund N. Relevance and consequences of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in gynecology. Arch Gynecol Obstet. 2009;280(5):851-854.
102. Haber J, Hopman W, Gomez M, Cartotto R. Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. J Burn Care Rehabil. 2005;26(1):33-41.
103. Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013;133(5):1197-1204.
104. Finkelstein Y, Soon GS, Acuna P, et al. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. 2011;128(4):723-728.
105. Magina S, Lisboa C, Leal V, Palmares J, Mesquita-Guimaraes J. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology. 2003;207(1):33-36.
106. Oplatek A, Brown K, Sen S, Halerz M, Supple K, Gamelli RL. Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burns Care Res. 2006;27(1):26-33.
107. Sheridan RL, Schulz JT, Ryan CM, et al. Long-term consequences of toxic epidermal necrolysis in children. Pediatrics. 2002;109(1):74-78.
108. Roujeau JC. Stevens-Johnson Syndrome and toxic epidermal necrolysis: improving the support to victims. Drug Safety. 2013;36(2):145-146.
109. Schulze Schwering M, Kayange P, van Oosterhout JJ, Spitzer MS. Severe eye complications from stevens-johnson syndrome in a human immunodeficiency virusinfected patient in Malawi. Am J Trop Med Hyg. 2013;89(1):162-164.
110. Butt TF, Cox AR, Oyebode JR, Ferner RE. Internet accounts of serious adverse drug reactions: a study of experiences of Stevens-Johnson syndrome and toxic epidermal necrolysis. Drug Safety. 2012;35(12):1159-1170.
111. Butt TF, Cox AR, Lewis H, Ferner RE. Patient experiences of serious adverse drug reactions and their attitudes to medicines: a qualitative study of survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. Drug Safety. 2011;34(4):319-328.